{"id":714715,"date":"2026-02-16T11:47:05","date_gmt":"2026-02-16T09:47:05","guid":{"rendered":"https:\/\/eba.com.ua\/?p=714715"},"modified":"2026-03-20T11:57:16","modified_gmt":"2026-03-20T09:57:16","slug":"klinichni-doslidzhennya-v-ukrayini-2022-2025-dynamika-vidnovlennya-ta-oriyentyry-na-majbutnye","status":"publish","type":"post","link":"https:\/\/eba.com.ua\/en\/klinichni-doslidzhennya-v-ukrayini-2022-2025-dynamika-vidnovlennya-ta-oriyentyry-na-majbutnye\/","title":{"rendered":"[:ua]\u041a\u043b\u0456\u043d\u0456\u0447\u043d\u0456 \u0434\u043e\u0441\u043b\u0456\u0434\u0436\u0435\u043d\u043d\u044f \u0432 \u0423\u043a\u0440\u0430\u0457\u043d\u0456 2022\u20132025: \u0434\u0438\u043d\u0430\u043c\u0456\u043a\u0430 \u0432\u0456\u0434\u043d\u043e\u0432\u043b\u0435\u043d\u043d\u044f \u0442\u0430 \u043e\u0440\u0456\u0454\u043d\u0442\u0438\u0440\u0438 \u043d\u0430 \u043c\u0430\u0439\u0431\u0443\u0442\u043d\u0454[:en]Clinical Trials in Ukraine 2022\u20132025: Recovery Dynamics and Future Outlook[:]"},"content":{"rendered":"

<\/p>\n

This publication draws on orders of the Ministry of Health of Ukraine regarding the conduct of clinical trials and the approval of substantial amendments (hereinafter, MoH Orders on CT\/SA), published on the official MoH website [1]<\/a>, as well as open data from the information resource of the State Expert Center of the Ministry of Health of Ukraine (SEC MoH) [2]<\/a>.<\/em><\/p>\n

The analysis covers MoH Orders on CT\/SA from May 2022 through December 2025, inclusive.<\/em><\/a><\/p>\n\t

\n\n\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\n\n\t\t\t\t\t\t\tIryna Magdik<\/span>\n\t\t\t\n\t\t\t\t\t\t\tExecutive Director of the EBA Clinical Trials Subcommittee<\/span>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t
\n\t\t\t\tThe years 2022\u20132025 became a period of both severe challenges and profound transformation for clinical trials in Ukraine. Despite the full scale war, the sector demonstrated remarkable resilience and a gradual recovery after an abrupt decline: the number of new clinical trial protocols and the network of clinical trial sites expanded several fold, and international sponsors have begun returning with new projects.\n\t\t\t<\/blockquote>\n\t\t\t\t\n\t<\/div>\n\n
\n

The expansion of trial site infrastructure, improvements in the regulatory environment, and uninterrupted functioning of the regulator ensured continuity and quality of clinical trial conduct. Against the backdrop of global shifts – digitalization, hybrid and decentralized models, and intensifying competition – Ukraine preserved key operational advantages. However, delays in harmonizing with the EU Clinical Trials Regulation (EU CTR) and integrating into CTIS pose significant risks to maintaining speed, securing investment, and sustaining participation in international research.<\/p>\n<\/div>\n

\n
\n

Four Years of Resilience: Recovery and Transformation Amid War<\/strong><\/h2>\n